Cardiol Therapeutics Inc.
CRDL
$1.17
$0.0857.87%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 107.16% | -2.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 83.26% | -9.26% | |||
| Operating Income | -83.26% | 9.26% | |||
| Income Before Tax | -93.75% | 29.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -93.75% | 29.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -93.75% | 29.26% | |||
| EBIT | -83.26% | 9.26% | |||
| EBITDA | -83.85% | 9.30% | |||
| EPS Basic | -90.58% | 30.73% | |||
| Normalized Basic EPS | -90.64% | 30.81% | |||
| EPS Diluted | -90.58% | 30.73% | |||
| Normalized Diluted EPS | -90.64% | 30.81% | |||
| Average Basic Shares Outstanding | 1.59% | 2.22% | |||
| Average Diluted Shares Outstanding | 1.59% | 2.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
